Efficacy of mefenamic acid in patients with a complaint of menorrhagia.
article
OA: closed
CC0
⤵ 43 in-corpus citations
AI-generated summary
Mefenamic acid significantly reduced menstrual blood loss by an average of 28.1% and bleeding duration in women with menorrhagia compared to placebo.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Sixty-nine patients with a convincing history of menorrhagia completed a 4-cycle double-blind randomized placebo-controlled crossover trial of mefenamic acid taken during menstruation. Only 30 of these patients demonstrated objective menorrhagia with a measured menstrual loss greater than 80 ml during the placebo cycles, but the remainder reported passing clots and/or using 2 pads at a time. Fourteen of these women (20%) had a loss of less than 35 ml while taking placebos. This raises serious questions about the establishment of menorrhagia based on history alone. Overall, there was a mean reduction of 28.1% in menstrual blood loss between placebo and mefenamic acid cycles (P less than .001). The greatest reduction recorded was 80%, and most of the large percentage reductions were seen in patients with high loss during placebo cycles. Significant reductions in blood loss (P less than .001) were seen in patients with ovulatory dysfunctional uterine bleeding and menorrhagia that developed after tubal interruption. There was also an indication based on small sample sizes that mefenamic acid reduced blood loss in women with anovulatory dysfunctional uterine bleeding, fibroids, intrauterine devices, and von Willebrand disease. No reduction was seen during the mefenamic acid cycle in the group with a loss of less than 35 ml during the placebo cycle. There was a significant shortening of duration of bleeding (P less than .003). Fifteen patients (21.7%) experienced no objective reduction in blood loss.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (43)
- Variation of outcome reporting in studies of interventions for heavy menstrual bleeding: a systematic review 2022
- The Menstrual Endometrium: From Physiology to Future Treatments 2022
- NSAIDs for heavy menstrual bleeding 2021
- Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding 2019
- Medical Management of Heavy Menstrual Bleeding 2015
- Menstrual Problems for the MRCOG and Beyond 2014
- Nonsurgical Management of Heavy Menstrual Bleeding 2013
- Heavy menstrual flow: current and future trends in management. 2013
- Dysfunctional uterine bleeding: from adolescence to menopause 2010
- Danazol for heavy menstrual bleeding 2007
- Benefits and Risks of Pharmacological Agents Used for the Treatment of Menorrhagia 2004
- Update on treatment of menstrual disorders 2003
- Dysfunctional Uterine Bleeding and its Management Strategy 2003
- Medical management of dysfunctional uterine bleeding 1999
- Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding 1998
- Dysfunctional uterine bleeding. 1998
- 4 Indications and alternatives to hysterectomy 1997
- Dysfunctional Uterine Bleeding 1997
- Managing menorrhagia. 1995
- Treating Menorrhagia in Primary Care: <i>An Overview of Drug Trials and a Survey of Prescribing Practice</i> 1995
- Menorrhagia—a pragmatic approach to the understanding of causes and the need for investigations 1994
- Nonsteroidal antiinflammatory drugs and reproduction 1993
- Medical management of menorrhagia 1992
- 8 Prostaglandins, prostaglandin inhibitors and their roles in gynaecological disorders 1992
- Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia 1992
- Management of Dysfunctional Uterine Bleeding 1992
- Treatment of Menorrhagia 1992
- Randomized Trial of 2 Hormonal and 2 Prostaglandin‐inhibiting Agents in Women with a Complaint of Menorrhagia 1991
- Risk-Benefit Assessment of Drugs Used for the Treatment of Menstrual Disorders 1991
- Levonorgestrel‐releasing intrauterine device in the treatment of menorrhagia 1990
- Management of Cyclical Menorrhagia with Prostaglandin Synthetase Inhibitor 1990
- Comparison between mefenamic acid and danazol in the treatment of established menorrhagia 1989
- 11 Treatment of menorrhagia 1989
- 6 Dysfunctional uterine bleeding 1989
- Endometrial prostaglandins in women with abnormal menstrual bleeding 1987
- Control of menorrhagia by the cyclo‐oxygenase inhibitors naproxen sodium and mefenamic acid 1987
- Eicosanoids, menstruation and menstrual disorders 1987
- Primary and myoma‐associated menorrhagia: role of prostaglandins and effects of ibuprofen 1986
- Treatment of Dysfunctional Uterine Bleeding with Danazol 1985
- Prostaglandins in the human uterus: An interaction between endometrium and myometrium 1985
- The relationship between menstrual blood loss and prostaglandin production in the human: Evidence for increased availability of arachidonic acid in women suffering from menorrhagia 1984
- Prostaglandins in menstrual fluid in menorrhagia and dysmenorrhoea 1984
- Prostaglandins and menstrual disorders. 1983
Source provenance
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0
· commercial use OK